Biocardia Inc (BCDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biocardia Inc (BCDA) has a cash flow conversion efficiency ratio of 1.556x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.66 Million) by net assets ($-1.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biocardia Inc net asset quality index to measure how much of total assets are equity-financed.
Biocardia Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Biocardia Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Biocardia Inc to evaluate the quality of earnings relative to operating cash generation.
Biocardia Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biocardia Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MENNICA SKARB.AB ZY -10
F:98S
|
0.398x |
|
Camplify Holdings Ltd
AU:CHL
|
-0.067x |
|
StarFlex Co. Ltd
KQ:115570
|
-0.017x |
|
RomReal Limited
OL:ROM
|
0.185x |
|
Bass Oil Ltd
AU:BAS
|
-0.041x |
|
Copaur Minerals Inc
V:CPAU
|
-0.008x |
|
VL E-Governance & IT Solutions Limited
NSE:VLEGOV
|
N/A |
|
Alarum Technologies Ltd.
NASDAQ:ALAR
|
-0.036x |
Annual Cash Flow Conversion Efficiency for Biocardia Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Biocardia Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Biocardia Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $895.00K | $-7.44 Million | -8.308x | +13.36% |
| 2024-12-31 | $837.00K | $-8.03 Million | -9.589x | -254.11% |
| 2023-12-31 | $-1.60 Million | $-9.97 Million | 6.222x | +388.22% |
| 2022-12-31 | $4.89 Million | $-10.56 Million | -2.159x | -116.07% |
| 2021-12-31 | $10.38 Million | $-10.37 Million | -0.999x | -55.05% |
| 2020-12-31 | $19.18 Million | $-12.36 Million | -0.644x | +83.83% |
| 2019-12-31 | $2.37 Million | $-9.45 Million | -3.985x | -36.53% |
| 2018-12-31 | $3.79 Million | $-11.07 Million | -2.919x | -274.52% |
| 2017-12-31 | $11.12 Million | $-8.67 Million | -0.779x | -190.51% |
| 2016-12-31 | $20.58 Million | $-5.52 Million | -0.268x | -1223.91% |
| 2015-12-31 | $13.87 Million | $331.00K | 0.024x | +51.08% |
| 2014-12-31 | $13.54 Million | $214.00K | 0.016x | +678.90% |
| 2013-12-31 | $13.31 Million | $27.00K | 0.002x | +108.70% |
| 2012-12-31 | $13.29 Million | $-310.00K | -0.023x | +90.19% |
| 2011-12-31 | $12.98 Million | $-3.09 Million | -0.238x | +81.76% |
| 2010-12-31 | $3.28 Million | $-4.28 Million | -1.304x | -301.89% |
| 2009-12-31 | $14.74 Million | $-4.78 Million | -0.325x | -28.78% |
| 2008-12-31 | $10.70 Million | $-2.70 Million | -0.252x | +67.22% |
| 2007-12-31 | $61.28K | $-47.12K | -0.769x | +85.32% |
| 2006-12-31 | $141.55K | $-741.46K | -5.238x | -103.10% |
| 2005-12-31 | $176.73K | $-455.82K | -2.579x | -231.63% |
| 2004-12-31 | $963.58K | $-749.42K | -0.778x | -338.65% |
| 2003-12-31 | $1.68 Million | $-297.66K | -0.177x | +24.45% |
| 2002-12-31 | $2.09 Million | $-491.22K | -0.235x | +47.81% |
| 2001-12-31 | $3.40 Million | $-1.53 Million | -0.450x | -103.53% |
| 2000-12-31 | $6.27 Million | $-1.38 Million | -0.221x | +51.39% |
| 1999-12-31 | $2.20 Million | $-1.00 Million | -0.455x | -120.78% |
| 1998-12-31 | $3.40 Million | $-700.00K | -0.206x | -68.82% |
| 1997-12-31 | $4.10 Million | $-500.00K | -0.122x | 0.00% |
| 1996-12-31 | $4.10 Million | $-500.00K | -0.122x | +96.68% |
| 1995-12-31 | $-71.75K | $263.39K | -3.671x | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more